Global report on diabetes. World Health Organization 2016.
Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008; 26: 2.
Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171-6.
Kim JA, Montagnani M, Koh KK, et al. Reciprocal relationships between insulin resistance and endothelial dysfunction: Molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888-904.
Du X, Edelstein D, Obici S, et al. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 2006; 116: 1071-80.
Hasegawa Y, Saito T, Ogihara T, et al. Blockade of the nuclear factor-κB pathway in the endothelium prevents insulin resistance and prolongs life spans. Circulation 2012; 125: 1122-33.
Chaudhuri A, Janicke D, Wilson MF, et al. Anti-Inflammatory and profibrinolytic effect of insulin in acute ST-Segment- Elevation myocardial infarction. Circulation 2004; 109: 849-54.
Vinik AI, Erbas T, Sun Park T, et al. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476-85.
Paneni F, Beckman JA, Creager MA, et al. Diabetes and vascular disease: Pathophysiology, clinical consequences and medical therapy: part I. Eur Heart J 2013; 34: 2436-43.
Geraldes P, King GL. Activation of protein kinase Cisoforms and its impact on diabetic complications. Circ Res 2010; 106: 1319-31.
Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49: 1939-45.
Du XL, Edelstein D, Dimmeler S, et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001; 108: 1341-8.
Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107: 1058-70.
Boyle PJ. Diabetes mellitus and macro vascular disease: Mechanisms and mediators. Am J Med 2007; 120: S12-7.
Katakami N. Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus. J Atheroscler Thromb 2018; 25: 27-39.
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology and management. JAMA 2002; 287: 2570-81.
Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003; 46: 760-5.
Paterson AD, Rutledge BN, Cleary PA, et al. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: The diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2007; 30: 2107-12.
Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26: 917-32.
Kannel WB, McGee DL. Diabetes and cardiovascular disease: The framingham study. JAMA 1979; 241: 2035-8.
Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 41: 2669-701.
Lehto S, Ronnemaa T, Pyorala K, et al. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996; 27: 63-8.
Almdal T, Scharling H, Jensen JS, et al. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke and death: A population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004; 164: 1422-6.
Schramm TK, Gislason GH, Køber L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: A population study of 3.3 million people. Circulation 2008; 117: 1945-54.
Bulugahapitiya U, Siyambalapitiya S, Sithole J, et al. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009; 26: 142-8.
Jensen LO, Maeng M, Thayssen P, et al. Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2012; 109: 629-35.
Machecourt J, Danchin N, Lablanche JM, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients. The EVASTENT matched-cohort registry. J Am Coll Cardiol 2007; 50: 501-8.
Woods SE, Smith JM, Sohail S, et al. The influence of type 2 diabetes mellitus in patients undergoing coronary artery bypass graft surgery: An 8-year prospective cohort study. Chest 2004; 126: 1789-95.
Aneja A, Tang WH, Bansilal S, et al. Diabetic cardiomyopathy: Insights into pathogenesis, diagnostic challenges and therapeutic options. Am J Med 2008; 121: 748-57.
Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: Evidence, mechanisms and therapeutic implications. Endocr Rev 2004; 25: 543-67.
Seferović PM, Paulus WJ. Clinical diabetic cardiomyopathy: A two-faced disease with restrictive and dilated phenotypes. Eur Heart J 2015; 36: 1718-27.
Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595-602.
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-12.
Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes: An update. Diabetes Care 2004; 27: 1879-84.
Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103: 2668-73.
Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The framingham study. Am J Cardiol 1974; 34: 29-34.
Jaffe AS, Spadaro JJ, Schechtman K, et al. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J 1984; 108: 31-7.
Iwasaka T, Takahashi N, Nakamura S, et al. Residual left ventricular pump function after acute myocardial infarction in NIDDM patients. Diabetes Care 1992; 15: 1522-6.
Galderisi M, Anderson KM, Wilson PW, et al. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991; 68: 85-9.
Rutter MK, Parise H, Benjamin EJ, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: Sex-related differences in the framingham heart study. Circulation 2003; 107: 448-54.
Eguchi K, Boden-Albala B, Jin Z, et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol 2008; 101: 1787-91.
Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: The strong heart study. Circulation 2000; 101: 2271-6.
Zarich SW, Arbuckle BE, Cohen LR, et al. Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J Am Coll Cardiol 1988; 12: 114-20.
Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014; 57: 660-71.
Agarwal G, Singh SK. Arrhythmias in type 2 diabetes mellitus. Indian J Endocrinol Metab 2017; 21: 715-8.
Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005; 105: 315-8.
Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: Incidence, risk factors and prognosis in the Manitoba follow-up Study. Am J Med 1995; 98: 476-84.
Dublin S, Glazer NL, Smith NL, et al. Diabetes mellitus, glycemic control and risk of atrial fibrillation. J Gen Intern Med 2010; 25: 853-8.
Ruigomez A, Johansson S, Wallander MA, et al. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol 2002; 55: 358-63.
Johansen OE, Brustad E, Enger S, et al. Prevalence of abnormal glucose metabolism in atrial fibrillation: A case control study in 75-year old subjects. Cardiovasc Diabetol 2008; 7: 28.
Schoen T, Pradhan AD, Albert CM, et al. Type 2 diabetes mellitus and risk of incident atrial fibrillation in women. J Am Coll Cardiol 2012; 60: 1421-8.
Ostgren CJ, Merlo J, Rastam L, et al. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab 2004; 6: 367-74.
Huxley RR, Filion KB, Konety S, et al. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 2011; 108: 56-62.
Vasiliadis I, Kolovou G, Mavrogeni S, et al. Sudden cardiac death and diabetes mellitus. J Diabetes Complications 2014; 28: 573-9.
Eranti A, Kerola T, Aro AL, et al. Diabetes, glucose tolerance and the risk of sudden cardiac death. BMC Cardiovasc Disord 2016; 16: 51.
Chen R, Ovbiagele B, Feng W. Diabetes and Stroke: Epidemiology, pathophysiology, pharmaceuticals and outcomes. Am J Med Sci 2016; 351: 380-6.
O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet 2010; 376: 112-23.
Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-22.
Jia Q, Zhao X, Wang C, et al. Diabetes and poor outcomes within 6months after acute ischemic stroke: The China national stroke registry. Stroke 2011; 42: 2758-62.
Knoflach M, Matosevic B, Rucker M, et al. Functional recovery after ischemic stroke - matter of age: Data from the Austrian Stroke Unit Registry. Neurology 2012; 78: 279-85.
Osei E, Fonville S, Zandbergen AAM, et al. Glucose in prediabetic and diabetic range and outcome after stroke. Acta Neurologica Scandinavica 2017; 135: 170-5.
Lange S, Diehm C, Darius H, et al. High prevalence of peripheral arterial disease and low treatment rates in elderly primary care patients with diabetes. Experimental Clin Endocrinol Diabetes 2004; 112: 566-73.
Aquino R, Johnnides C, Makaroun M, et al. Natural history of claudication: Long-term serial follow-up study of 1244 claudicants. J Vasc Surg 2001; 34: 962-70.
Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-24.
Clairotte C, Retout S, Potier L, et al. Automated ankle-brachial pressure index measurement by clinical staff for peripheral arterial disease diagnosis in nondiabetic and diabetic patients. Diabetes Care 2009; 32: 1231-6.
Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes - A review. Dia Med 2010; 27: 4-14.
Yokoyama H, Sone H, Honjo J, et al. Relationship between a low ankle brachial index and all-cause death and cardiovascular events in subjects with and without diabetes. J Atheroscler Thromb 2014; 21: 574-81.